Depending on age of acquisition, hepatitis B virus (HBV) can induce a cell-mediated immune response that results in either cure or progressive liver injury. In adult-acquired infection, HBV antigens are usually cleared, whereas in infancy-acquired infection, they persist. Individuals infected during infancy therefore represent the majority of patients chronically infected with HBV (CHB). A therapy that can promote viral antigen clearance in most CHB patients has not been developed and would represent a major health care advance and cost mitigator. Using an age-dependent mouse model of HBV clearance and persistence in conjunction with human blood and liver tissue, we studied mechanisms of viral clearance to identify new therapeutic targets. We demonstrate that age-dependent expression of the costimulatory molecule OX40 ligand (OX40L) by hepatic innate immune cells is pivotal in determining HBV immunity, and that treatment with OX40 agonists leads to improved HBV antigen clearance in young mice, as well as increased strength of T cell responses in young mice and adult mice that were exposed to HBV when they were young and developed a CHB serological profile. Similarly, in humans, we show that hepatic OX40L transcript expression is age-dependent and that increased OX40 expression on peripheral CD4 + T cells in adults is associated with HBV clearance. These findings provide new mechanistic understanding of the immune pathways and cells necessary for HBV immunity and identify potential therapeutic targets for resolving CHB.
INTRODUCTION
Hepatitis B virus (HBV) chronically infects ~300 million people and results in about 1 million deaths annually by causing liver failure and primary liver cancer [hepatocellular carcinoma (HCC)] (1). Adult pa tients who were infected before age 5 represent the major global res ervoir because infants clear HBV at much lower rates than adults. In contrast to children, adults mount a strong and diverse adaptive im mune response to HBV, which leads to viral clearance by mechanisms that are poorly understood (2) (3) (4) (5) (6) (7) . Because this strong adaptive im mune response has been associated with sustained remission of liver disease and a lower risk for liver failure and HCC, discovery of mecha nisms that tilt the immune response in patients with chronic HBV (CHB) infection toward a functional cure would open a gateway for developing definitive treatments.
To explore mechanisms that underlie HBV antigen clearance and the agedependent divergent disease outcomes during acute hepati tis B (AHB) infection, our laboratory developed a transgenic mouse model that faithfully mimics key aspects of the agedependent im munological differences in human HBV clearance and persistence (8, 9) . In this model, we use HBV transgenic mice crossed with mice genetically deficient in the recombinase RAG1 (Rag1 −/− ), which is required to generate mature B and T cells (10) . These mice express HBV antigens (HBVEnvRag ) in the liver, in the absence of an adaptive immune system that would otherwise be immunologically tolerant toward HBV antigens. Adop tive transfer of 10 8 HBVnaïve, syngeneic splenocytes from wildtype (WT) C57BL/6 or genetically modified mice reconstitutes the immune system and allows for the evaluation of contributions of cellular and soluble mediators in HBV pathogenesis (11) ) mirroring those seen in the peripheral blood of patients who develop CHB (8) . This model has provided an oppor tunity to uncover mechanisms leading to effective immunity and to experimentally modulate ineffective responses toward HBV clearance.
Data generated using this model, and our parallel studies in hu mans, have demonstrated that hepatic lymphoid organization and the competency of immune priming within the hepatic microenvironment pivotally guide HBVspecific T cell diversity, HBsAb seroconversion, and viral control (8, 9) . Our data support a model whereby effective HBV immunity involves intrahepatic T follicular helper (T FH ) cell priming, leading to local production of interleukin21 (IL21) at sites where IL21 is necessary for promoting effective antiviral responses by CD8 + T cells and B cells, which, in turn, lead to HBV clearance. The ineffective immune response generated in young mice and humans is primed in a hepatic microenvironment with diminished lymphoid organization and greatly diminished IL21 production and T FH num ber. The implications of this model suggest that agedependent ex pression of molecules on hepatic antigenpresenting cells (APCs) facilitate effective T and B cell responses to HBV. Here, we explore this hypothesis and examine the expression and role of the costim ulatory molecule OX40L on hepatic APCs and of its cognate recep tor OX40 on T lymphocytes in agedependent HBV immunity.
RESULTS

OX40 ligand expression on hepatic APCs is age-dependent, and age-dependent expression of OX40 on liver-derived CD4
+ T cells is observed during acute hepatitis To further elucidate the cells and molecules necessary for effective hepatic immune priming, we surveyed APCs from the livers of un infected young and adult mice for expression of costimulatory mol ecules known to be important in the initiation and expansion of T cell responses. Here, we focused on the expression of the tumor necrosis factor (TNF) receptor (TNFR)/TNF superfamily members OX40 and its partner OX40 ligand (OX40L) because of their known ability to control diverse aspects of immune function, including the regulation of conventional CD4 + and CD8 + T cell responses (12) (13) (14) (15) . These studies revealed agedependent differences in the expression of OX40L on he patic macrophages, monocytes, and dendritic cells (DCs). Specifically, realtime polymerase chain reaction (PCR) analysis of isolated non parenchymal liver cells from Rag1 −/− mice demonstrated a sevenfold increase of OX40L mRNA expression in 8 to 11weekold (adult) mice compared to 3weekold (young) mice (Fig. 1A) . Strikingly, expression of hepatic OX40L begins increasing to adult levels by age 5 weeks, at the same time that the immune response to HBV in our model be gins to convert to the adult profile (Fig. 1A) . To determine which cells in the liver express OX40L, nonparenchymal cells from the livers of adult and young Rag1 −/− mice were isolated and enriched for myeloid cells. We then analyzed and purified the various cell populations using flow cytometric analysis and fluorescenceactivated cell sorting (FACS). This revealed significant agedependent differences in the expression of OX40L on resident macrophages (P = 0.0005 and P < 0.0001), monocytes/monocytederived macrophages (P = 0.0035 and P = 0.0128), and DCs (P = 0.0087 and P = 0.0134) derived from livers of adult and young mice (Fig. 1B and fig. S1E ), without agedependent differences in the percentage or absolute numbers of these hepatic APCs ( Fig. 1C; representative FACS plots and absolute numbers in fig. S1 ). Consistent with the flow cytometry data, we demonstrated greater relative expres sion of OX40L mRNA on flowsorted APCs from both adult Rag1 −/− and WT mice (Fig. 1D and fig. S2A ). Thus, whereas the number of hepatic macrophages, monocytes, and DCs is not agedependent, the expression of OX40L on these hepatic APCs increases with age.
Expression of OX40L is limited to CD45 + leukocytes, and accord ingly, we did not detect expression of OX40L on liver sinusoidal en dothelial cells, hepatocytes, or stellate cells ( fig. S2B) . Notably, although the presence of the HBV transgene (without adoptive transfer of spleno cytes) does not influence OX40L expression in the young mice, it does increase the expression of OX40L in adult mice relative to Rag1 −/− mice ( fig. S2C ). The agedependent expression of OX40L is specific to the liver, because we observed similar (ageindependent) expression in the spleen and lymph nodes ( fig. S2D ). In addition, 12 weeks after the adoptive transfer of splenocytes, adult (HBVtgRag −/− ) mice that generated an effective immune response to HBV (HBsAg clearance and HBsAb production) maintain higher expression of OX40L com pared to adult mice that encountered HBV antigens when they were young and developed ineffective immunity ("chronic" HBVtgRag fig. S2E ). This increased expression of OX40L is specific to the liver, because splenocytes from these animals had similar expression of OX40L as compared to untransferred and chronic controls ( fig. S2F) .
To demonstrate biological effects of the agedependent expression of OX40L in the liver, we analyzed the expression of its receptor, OX40, on hepatic lymphoid cells derived from young and adult HBVEnvRag −/− mice at the peak of the HBVspecific T cell response 8 days after adop tive transfer of adult splenocytes. Percentages and absolute num bers of CD4 + T cells (P < 0.0001 and P < 0.0001) and OX40 + T cells (P < 0.0001 and P = 0.0001), as well as CD4 + T FH cells (P = 0.0035) and OX40 + CD4 + T FH (P = 0.008) cells, were significantly increased in the recipient adult mice compared to the young mice ( Fig. 1 (Fig. 2 , A to C, and fig. S4A ), clearance of HBsAg (Fig. 2D and fig. S4B ), and HBsAb sero conversion ( Fig. 2E and fig. S4C ). Interferon (IFN) enzymelinked immunospot (ELISpot) analysis of liver lymphocytes also revealed that expression of OX40 on donor splenocytes is necessary to generate diverse primary and memory HBVspecific hepatic CD4 + and CD8 + T cell responses (Fig. 2, F and G). The expression of OX40 was also necessary for the HBVspecific increase in hepatic CD4 + cells, in cluding T FH , as well as the hepatic IL21 expression that is crucial for effective HBV immunity (Fig. 2, H to J, and fig. S4D ), as we have pre viously shown (8) .
We −/− splenocytes developed clinical hepa titis or cleared HBsAg from the serum. Northern blot analysis was performed on total hepatic RNA to detect HBV envelope transcripts, and hepatic expression of HBsAg protein was determined by immuno histochemical staining. At day 7 after adoptive transfer, mice that re ceived either WT (P = 0.0082 and P = 0.0009) or Ox40 −/− (P = 0.017 and P = 0.0035) splenocytes both had a significant reduction of the 2.4 and 2.1kb viral transcripts, respectively, detected relative to the hepatic steadystate transcript content in the untransferred mice, where as at later time points (8 to 24 weeks), only the mice that received WT spleno cytes had reduction of these viral tran scripts (P = 0.047 and P = 0.044; Fig. 3 , B, C, and E). This finding of differences in the reduction of viral transcripts may reflect the differences observed in he patic IFN production detected in the transferred mice (Fig. 2, F and G) and is consistent with the known mechanisms of noncytolytic inhibition of HBV replication by IFN (16, 17) . Im munohisto chemical staining of liver for detection of HBsAg revealed expression of antigen in the livers of mice in all groups (Fig. 3, D and F) .
Together, these results suggest that loss of HBsAg from the serum of mice that received WT splenocytes and produced HBsAb is largely a result of antibody mediated antigen clearance (18) , with some contribution of cytokinemediated inhibition of viral transcription. Further more, the result that the mice that received Ox40 −/− splenocytes do not clear serum HBsAg likely reflects both a lack of pro duction of HBsAb (Fig. 2E and fig. S4C ) and decreased cytokine production in the liver (Fig. 2, F (20) . Specifically, these mice developed mild hepatic inflamma tion and weaker HBVspecific T cell re sponses, displayed weaker inhibition of hepatic viral replication, and failed to gen erate HBsAb but did generate HBcAb (Fig. 2, A to G; Fig. 3 , B, C, and E; and fig. S4 , A to E). In addition, just like young WT mice and young HBVnaïve humans, Ox40 −/− mice also generated HBsAb in response to the human recombinant HBV vaccine ( fig. S4F ).
When adult HBVEnvRag −/− mice were given a blocking antibody directed against OX40L on days 0, 2, 4, and 6 after adoptive transfer of WT spleno cytes, the early immune response and disease outcome paralleled the results demonstrated in adult HBVEnvRag −/− that received Ox40 −/− splenocytes (Fig. 4) . Specifically, the blocking antibody prevented clinical hepatitis (Fig. 4A and fig. S5A ), significantly limited the ex pansion of hepatic CD4 + T cells (P < 0.0001; fig. 4B ), limited the di versity of the HBVspecific hepatic CD4 + and CD8 + T cell responses (Fig. 4C) , and significantly decreased the hepatic expression of IL21 (P = 0.0054; Fig. 4D ). This early intervention of OX40L blockade in S5 , B and C). Thus, an OX40/OX40L interaction is crucial for effective HBV immunity and is likely required beyond the initial priming window.
An OX40 agonist can tilt the immune response toward HBV antigen clearance
In light of these findings, we tested the hypothesis that augmented sig naling through OX40 in young mice could beneficially alter the HBV specific immune response and disease outcome. Young HBVtgRag −/− mice received WT splenocytes and either an antiOX40 agonistic antibody or an isotype control antibody. In contrast to the young mice that received the control antibody, young mice treated with the OX40 agonist developed mild hepatitis, displayed increases in the percent ages and absolute numbers of CD4 + T cells and T FH cells, generated a more diverse HBVspecific T cell response, and 50% cleared HBsAg from plasma ( . Analysis of the HBV specific T cell responses in the OX40 agonisttreated young mice that cleared HBsAg revealed substantial differences in the strength and di versity of the T cell response compared with young mice that received the agonist and did not clear HBsAg (Fig. 5E ). Intriguingly, none of the young mice that cleared HBsAg produced HBsAb ( fig. S6E ). The fact that these mice do not seem to produce HBsAb likely reflects low CXCL13 expression in the livers of these young animals, which we have shown to be critical for hepatic B cell responses against HBV (9) . This finding suggests that a strong, diverse T cell response might facilitate effective HBV control even in the absence of HBsAb production. . Statistical significance was determined using the unpaired two-tailed t test (**P < 0.01 and ***P < 0.001; n = 5 mice). Bars represent means ± SEM. (J) Expression of various cytokine mRNAs relative to Gapdh was detected by RT-PCR on mRNA from liver lymphocytes 8 days after adoptive transfer (n ≥ 5). Bars represent means ± SEM. Statistical significance was determined using the unpaired two-tailed t test (*P < 0.05).
We then tested the hypothesis that signaling through OX40 could augment the HBV immune response in adult chronic HBVtgRag −/− mice that received WT splenocytes when they were 3 weeks of age and had developed the serological profile of an HBVspecific immune response that correlates with viral persistence. Specifically, 3weekold HBVtgRag −/− mice received WT splenocytes and were allowed to age to 12 weeks. All mice were confirmed to have the serological profile of chronic inactive HBV, including no ALT rise, HBsAg persistence, and lack of HBsAb seroconversion. At 12 weeks after adoptive trans fer, the mice received eight doses of either OX40 agonist antibody or isotype control antibody over 3 weeks (Fig. 5F ), or three doses of either OX40 agonist or isotype control antibody, followed by an addi tional four doses beginning at week 24 after adoptive transfer ( To assess the translational relevance of our findings, we analyzed rel ative expression of OX40L mRNA in paraffinembedded uninfected human liver biopsy tissue from infant (ages 6 to 12 weeks) and adult livers and found that OX40L is expressed in an agedependent manner in human liver (Fig. 6A) , similar to that found in the mice. To assess the CD45 + APCs in human liver, we analyzed the expression of the macrophage/monocyte selective markers CD14 and CD68 and R a g − / − u n t r a n s f e r r e d HBsAg-specific antibody and counterstained with hematoxylin. Stained sections were scored by a pathologist blinded to sample identities using the scoring system shown in (F); 0, no staining; 1, multifocal granular or diffuse staining in hepatocytes involving <25% of section; 2, granular or diffuse staining around centrilobular hepatocytes with no staining in portal regions; 3, diffuse positivity of hepatocytes restricted to centrilobular region; granular cytoplasmic positivity in remaining hepatocytes; and 4, diffuse positivity of hepatocytes restricted to centrilobular and mid zonal regions; granular cytoplasmic positivity in remaining hepatocytes. n ≥ 4 for all groups except Rag −/− untransferred, where n = 2. Bars represent means ± SEM.
observed no increase in these transcripts in adult livers compared to infant livers ( fig. S7 ). This finding suggests that similar to mice, the number of hepatic macrophages and monocytes in humans is not age dependent, whereas the expression of OX40L on these he patic APCs increases with age.
To seek parallels between functional data from our mouse model and the HBV immune response in humans, we examined PBMC from HBVinfected and control patients for evidence of an association be tween CD4 + T cell expression of OX40 and an effective immune re sponse. These studies revealed that like adult mice, adult patients with AHB infection have increased numbers of CD4 + T cells, and a greater percentage of these CD4 + T cells express OX40 during the primary immune response compared to adult patients with CHB (Fig. 6C) . Furthermore, this increase in circulating OX40 + T cells in patients with AHB was not observed during the ineffective immune response that occurs in patients with CHB during a hepatitic flare or in patients with inactive CHB (Fig. 6, B and C, and fig. S8 ). Thus, such increases are distinctly observed in patients who clear HBV and are not seen in chronically infected patients with similar levels of serum HBV DNA and liver inflammation or in patients with inactive CHB (Fig. 6C) . We did not detect a significant difference in the percentage of circu lating T FH or CD8 + T cells in these patientderived peripheral blood samples (Fig. 6B) .
DISCUSSION
Chronic infection with HBV afflicts up to 300 million people and is the world's leading cause of cirrhosis, liver failure, and HCC. Although CHB can usually be suppressed by longterm antiviral therapy, mod ern treatments must typically be taken indefinitely because they rarely induce durable immunity and lead to sustained HBsAg clearance.
Definitive, more costeffective therapies are urgently needed that can promote HBV antigen clearance and immunity and, ultimately, low ered risk of HCC and cirrhosis in the millions of people with CHB.
A clear mechanistic understanding of the events that lead to failed HBV immunity should facilitate the development of new therapeu tics, but gaining this knowledge has been difficult. The primary ob stacle to human research stems from the fact that most patients who fail to clear HBV were infected as infants or young children, years before infection became clinically evident. Therefore, the early events in immune activation to HBV in most patients cannot be studied con temporaneously. Thus, experiments aimed at understanding failed immunity to HBV, and uncovering new therapeutic approaches to modulate immunity, must primarily rely on animal models, coupled with focused experiments using blood and tissue from patients to val idate the models, as developed here.
Using a mouse model of HBV infection that recapitulates the key dichotomous differences in HBV immunity between infection in early life and adulthood in humans, we show a critical role for agedependent expression of OX40L by hepatic APCs in the initiation of an HBV immune response that leads to effective immunity. Our data firmly implicate diminished hepatic OX40L expression in young mice and young humans as playing a major role in the ineffective immune re sponse that results in CHB. Furthermore, we also show that effective immunity to HBV, including IL21 production by T FH , a strong and diverse primary T cell response, HBsAb seroconversion, and HBsAg clearance, is OX40/OX40Ldependent. The HBV agedependent as pect aside, our data are consistent with studies demonstrating a role for OX40/OX40L interaction in the expansion and maintenance of T cell responses against other viruses (12) (13) (14) (15) (21) (22) (23) (24) .
As with all animal models of human disease, certain aspects of natural HBV infection are not recapitulated, for example, the mice Bars represent means ± SEM. Statistical significance was determined using the unpaired two-tailed t test (*P < 0.05 and ***P < 0.001; n = 6). (C) HBV-specific T cell responses were measured using IFN- ELISpot assay 8 days after adoptive transfer. Threshold defining a positive response is ≥2× the baseline (dashed line; n = pooled from four mice). (D) Relative Il21 expression compared to Gapdh was detected by RT-PCR on mRNA from liver lymphocytes isolated 8 days after adoptive transfer. Bars represent means ± SEM. Statistical significance was determined using the unpaired two-tailed t test (**P < 0.01; n = 6).
are not naturally infected by HBV and do not form cccDNA (cova lently closed circular DNA) but are producing transgenic HBV pro teins and virions. In addition, in the HBV transgenic model, a naïve immune system abruptly encounters hepatocytes expressing high levels of HBV antigen or virions. It is for these reasons that we went on to probe hepatic immunity and the immune response to HBV using cells and tissue from patients, guided by our findings in the mouse model. These comparative studies of patients acutely and chronically infected with HBV additionally support that adults with CHB have impaired OX40/40Ldependent immunity, which has clear implica tions for potential therapies. Our demonstration that an OX40 agonist can tilt the immune response toward HBV clearance in young mice and in adult chronic mice that encountered antigen when they were young opens new avenues for treating CHB in humans. Preclinical studies using tumor models demonstrate that tumorassociated, antigenspecific CD8 + T cells increase in quantity after OX40 agonist immunotherapy, and OX40 agonists, plus and minus checkpoint blockade, lead to reduced tumor growth and improved overall sur vival (25-28). Our data suggest that the OX40/OX40L pathway is crucial for effective HBV immunity and that OX40 agonists have po tential in definitively treating CHB by augmenting the virusspecific T cell response. However, similar to use in tumor models, OX40 ago nists alone might not be sufficient to fully reprime the immune response to HBV. Thus, analogous to approaches for cancer immunotherapy, OX40 agonists for the treatment of CHB might be used either alone or in combination with other immune modulatory agents that target pathways that we and others have demonstrated to be important in the generation of an immune response that leads to viral control or tumor regression (8, 9, 11, (25) (26) (27) (29) (30) (31) (32) (33) (34) . Our data suggest that the OX40/OX40L pathway functions in natural hepatic immunity, which establishes its potential for therapeutic manipulation in treating CHB and a variety of other infectious, immune, and neoplastic liver diseases.
MATERIALS AND METHODS
Study design
We sought to elucidate mechanistic understanding of the immune pathways and cells necessary for HBV immunity and to identify po tential therapeutic targets for resolving CHB. To accomplish this, studies were designed in five parts: (i) to identify agedependent ex pression of costimulatory molecules on APCs from the livers of young and adult mice, which are known to be important in the initiation and expansion of T cell responses; (ii) to study the role of an identified receptor/ligand pair, OX40/OX40L, in an established transgenic mouse model that mimics key aspects of the agedependent immunologi cal differences in human HBV clearance and persistence; (iii) to test whether augmented signaling through OX40 in mice could benefi cially alter the HBVspecific immune response and disease outcome; (iv) to test whether agedependent differences in the expression of OX40L observed in mouse livers might be recapitulated in humans; and (v) to seek parallels between functional data from our mouse model and the HBV immune response in human PBMCs. For all mouse experiments, mice were age and sexmatched (both sexes in cluded) and were assigned randomly to the different experimental groups. Data collection was terminated at relevant clinical and bio logical time points. Mice were kept in microisolator cages in a specific pathogen-free facility, and the University of California, San Francisco (UCSF) Institutional Animal Care and Use Committee approved all animal experiments carried out in this study. For comparative studies using human cells and tissue, sample size was determined by match ing the number of mice included for data generation in the respective experiments and/or the availability of pertinent, clinically annotated samples in our biorepository (6 to 24 individuals). No outlier analysis was performed. UCSF and California Pacific Medical Center institu tional review boards approved all human studies. Primary data for all studies are in table S3.
Mice and experimental system WT C57BL/6 mice were purchased from Jackson Laboratory. HBVEnvRag −/− and HBVRplRag −/− mice were previously described (11) . Briefly, HBVEnvRag −/− mice were generated using HBVEnv −/− C57BL/6 mice for 15 generations. HBVRplRag −/− mice contain a terminally redundant HBV DNA construct and produce infectious virus in their hepatocytes and in the proximal convoluted tubules of their kidneys. Young (3 to 4 weeks old, before weaning) or adult (8 to 12 weeks old) HBVtgRag −/− mice were given 10 8 syn geneic splenocytes pooled from adult (8 to 12 weeks) WT or mutant mouse strains in 0.5 ml of phosphatebuffered saline via tail vein injection. Mice were followed for plasma ALT using an ALTL3K kit (Sekisui Diagnostics) on a Cobas Miras Plus analyzer (Roche Di agnostics). C57BL/6, Ox40 −/− mice were generated at UCSF (37), but provided to us by M. Croft (La Jolla Institute for Allergy and Immunology). Bars represent means ± SEM. Statistical significance was determined using Tukey's analysis of variance (ANOVA) multiple comparison test (*P < 0.05 and **P < 0.01).
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HBV protein assays Plasma was collected and assayed for the presence of HBsAg by using ETIMAK2 Plus (DiaSorin). HBsAg results are reported as positive or negative, determined by parameters programmed by DiaSorin in an ELx800 plate reader (BioTek). Total HBsAb was quantified by using ETIABAUK PLUS and ABAU standard set (DiaSorin). Plas ma from transferred HBVRplRag / mice was assayed for the pres ence of total HBcAb using ETIABCOREK PLUS (DiaSorin).
Cell preparations
Lymphocytes were isolated from the liver after perfusion and digestion. Briefly, mice were perfused via the inferior vena cava using digestion media [RPMI 1640 containing 5% fetal bovine serum (FBS), crude collagenase (0.2 mg/ml; Crescent Chemical), and DNase I (0.02 mg/ml; Roche Diagnostics)]. Livers were forced through a 70m filter using a syringe plunger, and debris was removed by centrifugation (30g for 3 min). Supernatants were collected and centrifuged for 10 min at 650g. Lymphocytes were isolated from the Percoll interface using a 60%:40% Percoll gradient. Myeloid fractions were isolated from the liver after 6 min of perfusion via the inferior vena cava using diges tion media as above. Livers were chopped and further digested with liberase and DNase I (Roche Diagnostics) [1 Wünsch Units (WU) and 0.8 mg, respectively, in 10 ml of RPMI 1640 containing 5% FBS] for 30 min at 37°C in a shaking water bath. Livers were forced through a 70m filter, and debris was removed by centrifugation (30g for 3 min). Supernatants were collected and centrifuged for 10 min at 650g. Cells were isolated from the interface of a 25%:50% Percoll gradient.
Flow cytometry
Lymphocytes and myeloid cells were prepared as above. Cells were stained according to standard protocols with combinations of the following antimouse antibodies: OX40APC (eBioscience; clone, OX86), CD4FITC (eBioscience; clone, GK1.5), CD4APCCy7 (BD Bio sciences; clone, GK1.5), CD8-Pacific Orange (Life Technologies; clone, 5H10), CD8-Pacific Blue (BD Biosciences; clone, 536.7), TCRbPacific Blue (BD Biosciences; clone, H57597), TCRbPE (BD Biosciences; clone, H57597), NK1.1PECy7 (eBioscience; clone, PK136), CD19-Alexa Fluor 700 (eBioscience; clone, ebio1D3), CD19APC Cy7 (BD Biosciences; clone, 1D3), CXCR5biotin (BD Biosciences; clone, 2G8), OX40LPE (eBioscience; clone, RM134L), F4/80PECy7 (eBioscience; clone, BM8), CD11bPerCPCy5.5 (BD Biosciences; clone, M1/70), CD11cAPC (eBiosciences; clone, N418), major histo compatibility complex II-efluor 450(IA/IE) (eBioscience; clone, M5/114.15.2), Ly6gPerCPCy5.5 (BD Biosciences; clone, 1A8), and Ly6cAF700 (BD Biosciences, clone: AL21). When applicable for biotinylated antibodies, cells were stained with secondary QDot 605-conjugated streptavidin (Life Technologies). Cells were analyzed using an LSR II flow cytometer (BD Biosciences) and FlowJo soft ware (TreeStar) or sorted on an Aria III (BD Biosciences).
Enzyme-linked immunospot
IFN ELISpot assays (BD Biosciences) were performed on unstim ulated liver lymphocytes. Liver lymphocytes were prepared as de scribed above. Peptide pool ELISpot assays were performed using IFN ELISpot assays plated with lymphocytes from transferred ani mals combined 1:1 with Rag1 −/− splenocytes to provide optimal APC stimulation. Fifteenmer peptides were generated across the whole envelope protein with 11 overlapping amino acids between peptides (SigmaAldrich), and 12 to 14 sequential peptides were combined in seven pools. Cells were incubated with peptides at a final concen tration of 5 g/ml for each peptide. ELISpot was performed follow ing the manufacturer's instructions (BD Biosciences). Later in our studies, we identified dominant and subdominant epitopes within the peptide pools and incubated with those identified peptides at a final concentration of 5 g/ml (table S2) 
Liver hematoxylin and eosin histology
Liver tissue was fixed in 4% paraformaldehyde (PFA) or 10% formalin and embedded in paraffin blocks. Fivemicrometer slices were cut. PFA and formalinfixed tissues were stained with hematoxylin and eosin (H&E) according to standard protocols by the Gladstone His tology and Light Microscopy Core and scored by a pathologist who was blinded to sample identity.
RNA extraction and real-time PCR
RNA isolated from lymphocytes was prepared using an RNeasy micro kit (Qiagen) with vortex and QIAshredder (Qiagen) disruption. RNA isolated from liver tissue was prepared using an RNeasy mini kit (Qiagen) using bead beat lysing (MP Biomedicals) and QIAshredder (Qiagen) disruption. cDNA was generated on 0.25 to 1.00 g of RNA using a iScript cDNA synthesis kit (BioRad). Realtime PCR was per formed on 2.5 l of cDNA product using iTaq Universal SYBR Green Supermix with ROX (BioRad) and the following mouse gene prim ers: Gapdh, 5′GGAGCGAGACCCCACTAACA3′ (forward) and 5′ACATACTCAGCACCGGCCTC3′ (reverse); Il21, 5′TCATCA TTGACCTCGTGGCCC3′ (forward) and 5′ATCGTACTTCTCCA CTTGCAATCC3′ (reverse); and Ox40l, 5′TCTGTGCTTCATC TATGTCTGC3′ (forward) and 5′CATCCT CACATCTGGTAACTGC3′ (reverse). Realtime PCR was performed on the 7300 RealTime PCR System (Applied Biosystems).
HBV transcript measurement by Northern blot RNA was extracted from flashfrozen liver pieces collected 1, 8, or 24 weeks after adoptive transfer of HBVRplRag −/− recipient mice with either WT or Ox40 −/− splenocytes using a modified TRIzol extraction (38) . Briefly, 1 ml of TRIzol (Life Technologies) was added to 25 mg of tissue and homogenized at 6000 rpm for 30 s using the MagNA Lyser instrument (Roche). RNA was extracted into the aqueous phase with the addition of 0.2 ml of chloroform (SigmaAldrich) and precipitated in 0.5 ml of isopropanol (SigmaAldrich). The pellet was washed with 1 ml of 75% ethanol and resuspended in RNasefree water. Tenmicroliter RNA samples were separated by denaturizing 1.2% agarose gel electrophoresis with reagents from the NorthernMax Kit (ThermoFisher) and transferred to a Nytron membrane using the TurboBlotter apparatus (SigmaAldrich). A DIGlabeled (−) strand HBV RNA probe was transcribed from Sca I-linearized pGEM3Z HBV plasmid with the DIG Northern Starter Kit (SigmaAldrich) ac cording to the manufacturer's instructions. Hybridization at 68°C, washes, and detection with CDPStar were carried out according to the DIG Wash and Block buffer set instructions (SigmaAldrich), and images were acquired with the Azure c300 system (Azure Biosystems). HBV envelope transcript abundance was quantitated using ImageJ software analysis (39) of HBV envelope large (2.4 kb) and middle/ small (2.1 kb) RNA transcript band intensities detected on the North ern blots and normalized to detected 18S RNA band intensities for each sample.
HBsAg protein detection and scoring by immunohistochemistry
Liver tissue was collected 1, 8, or 24 weeks after adoptive transfer of HBVRplRag −/− mice with either WT or Ox40 −/− splenocytes and fixed in 10% formalin for 24 hours. Fixed liver tissue was subsequently processed and embedded in paraffin following standard protocols. Paraffin blocks were sectioned at 5 m, and immunohistochemistry for HBV surface antigen was performed on these formalinfixed paraffin embedded (FFPE) tissues. Briefly, molecular localization studies were conducted using a Ventana Discovery XT autostainer (Ventana Med ical Systems, Roche Group). FFPE tissues were sectioned at 5 m, barcoded, and then placed in the autostainer for paraffin extraction and rehydration. A rabbit polyclonal antibody (BioRad) was found to be specific for HBV surface antigen and was used at a final con centration of 1.3 g/ml. Antigen retrieval (CC1 mild; Ventana Med ical Systems), primary antibody dilution, incubation temperature and duration, detection technique, and 3,3′diaminobenzidine (DAB) chromogen (ChromoMap DAB Kit, Ventana Medical Systems) were optimized on sections of HBVinfected positive control liver (Newcomer Supply) and included evaluation of isotypematched irrelevant anti body controls, as well as known negative liver tissue. Slides were counterstained (hematoxylin, Ventana Medical Systems) and cover slipped (Micromount, Leica Biosystems). HBsAg expression was scored qualitatively by an unbiased pathologist using the following criteria: 0, no staining; 1, multifocal granular or diffuse staining in hepatocytes involving <25% of section; 2, granular or diffuse staining around centrilobular hepatocytes with no staining in portal regions; 3, diffuse positivity of hepatocytes restricted to the centrilobular region; gran ular cytoplasmic positivity in the remaining hepatocytes; 4, diffuse positivity of hepatocytes restricted to the centrilobular and mid zonal regions; granular cytoplasmic positivity in the remaining hepatocytes; and 5, diffuse positivity of all hepatocytes.
Patient samples and OX40L RNA expression
Twentyfour infants (6 to 12 weeks of age) were liverbiopsied to rule out biliary atresia at the UCSF Medical Center. Six of these patients were found to have biliary atresia, 6 had neonatal nonviral hepatitis, 10 were found to have a nonspecific liver disease diagnosis, including cholestasis and ductopenia, and 2 had an unknown diagnosis. Nine adult liver samples were obtained from donor livers before trans plantation. RNA from FFPE tissue was extracted using the RNeasy FFPE kit (Qiagen) following the manufacturer's instructions. Isolated RNA (150 ng) was reversetranscribed using the QuantiFast Probe assay (Qiagen) and amplified using specific probes and primers to human GAPDH and OX40L or using by the prime PCR probe assay (BioRad) for CD14, CD68, and GAPDH. PBMC were obtained from eight patients with confirmed AHB infection at the time of active hepatitis and confirmed subsequent viral clearance and HBsAb seroconversion, eight patients with con firmed CHB infection exhibiting a flare of disease (ALT rise), as well as six patients with confirmed CHB with inactive disease (normal ALT), and six healthy individuals. Cells were stained according to standard protocols with combinations of the following antihuman antibodies: TCRabPECy7 (BioLegend; clone, IP26), CD4BV785 (BioLegend; clone, OKT4), OX40PE [BioLegend; clone, BerACT35 (ACT35)], ICOS-PerCP-eFluor 710 (eBioscience; clone, ISA3), CXCR5APCs (BD Biosciences; clone, RF8B2), CD8BV570 (BioLegend; clone, RPAT8), CD56BV605 (BioLegend; clone, HCD56), CD16AF700 (BioLegend; clone, 3G8), and CD19BV650 (BioLegend; clone, HIB19).
Acutely infected HBV patients had confirmed elevated viral loads 
Statistical analysis
Statistics were performed using Prism (Graph Pad Software). Statis tical significance was determined by twotailed unpaired Student's t test (when two groups were compared), twotailed paired Student's t test (for longitudinal analyses of the same mice), or Tukey's analy sis of variance (ANOVA) multiplecomparison test (when more than two groups were compared). For significance of HBsAg clearance, in which one of two possible outcomes was compared (clearance ver sus no clearance), Fisher's chisquare test was used. For ordinal or ranked data (histology scores), the MannWhitney rank sum test was used. In all figures with multiple n, data are presented as means ± SEM. P < 0.05 was considered significant.
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